Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 4/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 12/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13952022 | 0.87 | HSD17B2 (0.45) | STSAKR1C3HSD17B2ABCB11MEN1 | |
| SCHEMBL13952156 | 0.81 | STS (0.56) | STSCYP19A1ABCB11MEN1LMNA | |
| SCHEMBL13952148 | 0.81 | STS (0.56) | STSCYP19A1ABCB11MEN1ESR1 | |
| SCHEMBL13951923 | 0.79 | STS (0.72) | STSCYP19A1LMNAESR1MAPT | |
| SCHEMBL17525967 | 0.78 | SHBG (0.53) | STSCYP19A1ABCB11KDM4EMEN1 | |
| SCHEMBL13951924 | 0.77 | STS (0.69) | STS | |
| SCHEMBL14048707 | 0.77 | SHBG (0.49) | STSCYP19A1ABCB11KDM4EMEN1 | |
| SCHEMBL30291860 | 0.76 | STS (0.65) | STS | |
| SCHEMBL13952013 | 0.76 | STS (0.65) | STS | |
| SCHEMBL7643054 | 0.75 | AKR1C3 (0.71) | STSAKR1C3HSD17B2ABCB11ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042844-A1 | 17ALPHA-SUBSTITUTED STEROIDS AS SYSTEMIC ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS | ENDORECHERCHE, INC. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042844-A1 | 17ALPHA-SUBSTITUTED STEROIDS AS SYSTEMIC ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, SRD5A1 | STS 142/4885CYP19A1 8/4885AKR1C3 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.